Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-6284
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWölfinger, Pascal-
dc.contributor.authorEpp, Katharina-
dc.contributor.authorSchaefer, Lukas-
dc.contributor.authorKriege, Diana-
dc.contributor.authorTheobald, Matthias-
dc.contributor.authorBopp, Tobias-
dc.contributor.authorWagner-Drouet, Eva-Maria-
dc.date.accessioned2021-08-16T08:56:45Z-
dc.date.available2021-08-16T08:56:45Z-
dc.date.issued2020-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/6294-
dc.description.abstractAllogeneic haematopoietic stem cell transplantation (HSCT) after a reduced-intensity conditioning (RIC) regimen with fludarabine, melphalan and alemtuzmab is an effective therapy for haematological malignancies. Alemtuzumab, a monoclonal antibody against CD52, a glycosylphosphatidylinositol-anchor-bound surface protein on lymphocytes, depletes T cells to prevent graft-versus-host disease (GVHD). Despite this, acute and chronic GVHD (a/cGVHD) remain life-threatening complications after HSCT. The aim of the present study was to identify parameters to predict GVHD. In 69 patients after HSCT, T-cell subsets were functionally analysed. Reconstitution of CD52neg T cells and CD52neg regulatory T cells (Tregs) correlated with onset, severity and clinical course of aGVHD. Patients with aGVHD showed significantly lower levels of CD52pos T cells compared to patients with cGVHD or without GVHD (P < 0·001). Analysis of T-cell reconstitution revealed a percentage of <40% of CD52posCD4pos T cells or CD52pos Tregs at day +50 as a risk factor for the development of aGVHD. In contrast, CD52neg Tregs showed significant decreased levels of glycoprotein A repetitions predominant (GARP; P < 0·001), glucocorticoid-induced TNFR-related protein (GITR; P < 0·001), chemokine receptor (CXCR3; P = 0·023), C-C chemokine receptor type 5 (CCR5; P = 0·004), but increased levels of immunoglobulin-like transcript 3 (ILT3; P = 0·001), as well as a reduced suppressive capacity. We conclude that reconstitution of CD52neg T cells and CD52neg Tregs is a risk factor for development of aGVHD.en_GB
dc.language.isoengde
dc.rightsCC BY-NC*
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleCD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimenen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-6284-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleBritish journal of haematologyde
jgu.journal.volume191de
jgu.journal.issue2de
jgu.pages.start253de
jgu.pages.end262de
jgu.publisher.year2020-
jgu.publisher.nameWiley-Blackwellde
jgu.publisher.placeOxford u.a.de
jgu.publisher.urihttps://doi.org/10.1111/bjh.16706de
jgu.publisher.issn1365-2141de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1111/bjh.16706
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
woelfinger_pascal-cd52-negative_-20210816104941103.pdf1.22 MBAdobe PDFView/Open